CLAIM CARD
Mechanistically, the evidence suggests aspirin may modulate immune cell populations and inflammatory pathways through distinct biological mechanisms. Areia 2025 demonstrated a shift toward tolerogenic NK cell phenotypes (CD56 bright) with concurrent reduction in total NK cells, consistent with anti-inflammatory immunomodulation. The mechanistic substrate underlying He 2026's findings on fecal microbiota transplantation points to gut-liver axis modulation as a pathway for reducing hepatic inflammation, with significant mean differences in ALT levels. Sattui 2026's RIGHT trial design targets inflammation specifically in older adults with functional limitations, recognizing that inflammaging represents a key geroprotection target, though the trial is ongoing and no efficacy data are yet available from this population.
Evidence grade: exploratory
Contradiction status: none
Publication: 4ff5f065-8b09-4580-9cbc-da14dbcaa1fa
Provenance: Derivation Web chain
Citation Support
source_1Flensted-Jensen 2025source_2Saeed 2026source_3Zhu 2026source_4Navarese 2026source_5Yan 2024